Drug Profile
GR 92754
Alternative Names: GR-92754Latest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiprotozoals; Small molecules
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pneumocystis pneumonia; Toxoplasmosis
Most Recent Events
- 06 Dec 2000 Profile reviewed but no significant changes made
- 10 Feb 1999 No-Development-Reported for Pneumocystis pneumonia in United Kingdom (Unknown route)
- 10 Feb 1999 No-Development-Reported for Toxoplasmosis in United Kingdom (Unknown route)